Quick Takeaways
- PHIO - Phio Pharmaceuticals Corp. has 12 insiders with reported activity on this page.
- Net insider value flow over the last year: +$49,311.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 12 Insiders of Phio Pharmaceuticals Corp.
- Symbol
- PHIO on Nasdaq
- Location
- King Of Prussia, PA
What Changed
- Buy value: $49,311; sell value: $0.
- Net share flow: +32,700.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$49,311.
Buys
$49,311
Shares: 32,700
Insiders: 2
Sells
$0
Shares: 0
Insiders: 0
Net
+$49,311
Shares: +32,700
Insiders: 2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 20,000 | 0 | $22,300 | $0 | +$22,300 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 12,700 | 0 | $27,011 | $0 | +$27,011 |
Phio Pharmaceuticals Corp. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert J. Bitterman | Chairman, Pres. & CEO, Director | $419,649 | +$38,711 | +10% | Mixed | 05 Feb 2026 |
| Gerrit Dispersyn | President & CEO, Director | $320,614 | Mixed | 01 Mar 2022 | ||
| Lisa Cabott Carson | Chief Financial Officer | $95,880 | Mixed | 05 Feb 2026 | ||
| Robert L. Ferrara | Director | $82,959 | +$10,600 | +15% | Mixed | 11 Sep 2025 |
| Patricia A. Bradford | Director | $46,564 | Mixed | 05 Feb 2026 | ||
| David H. Deming | Director | $38,556 | Mixed | 05 Feb 2026 | ||
| Curtis Lockshin | Director | $35,858 | Mixed | 05 Feb 2026 | ||
| Jonathan E. Freeman | Director | $33,308 | Mixed | 05 Feb 2026 | ||
| H. Paul Dorman | Director | $30,759 | Mixed | 15 Feb 2022 | ||
| Caitlin Kontulis | Secretary & VP Finance & Admin | $10,196 | Mixed | 01 Mar 2024 | ||
| Robert M. Infarinato | Vp, Cfo | $8,140 | Mixed | 11 Sep 2024 | ||
| Geert Cauwenbergh | Director | $6,395 | Mixed | 17 Feb 2023 |
Top shareholders of Phio Pharmaceuticals Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
— |
9.9%
|
1,194,719
|
$1,409,768 | +$544,422 | 31 Dec 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
9.1%
|
1,142,556
|
$1,348,216 | +$840,816 | 31 Dec 2025 | |
| Orca Capital AG |
13D/G
|
— |
4.9%
|
538,707
|
$770,351 | -$231,251 | 08 Dec 2025 | |
| Robert J. Bitterman |
3/4/5
|
Chairman, Pres. & CEO, Director |
3.4%
|
411,421
|
$419,649 | +$38,711 | 05 Feb 2026 | |
| Gerrit Dispersyn |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
212,327
|
$320,614 | — | 01 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.77%
|
92,638
|
$97,269 | — | 31 Dec 2025 | |
| Lisa Cabott Carson |
3/4/5
|
Chief Financial Officer |
0.78%
|
94,000
|
$95,880 | — | 05 Feb 2026 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.73%
|
87,628
|
$92,009 | — | 31 Dec 2025 | |
| Robert L. Ferrara |
3/4/5
|
Director |
0.32%
|
38,766
|
$82,959 | +$10,600 | 11 Sep 2025 | |
| Patricia A. Bradford |
3/4/5
|
Director |
0.38%
|
45,651
|
$46,564 | — | 05 Feb 2026 | |
| Cetera Investment Advisers |
13F
|
Company |
0.35%
|
42,500
|
$44,625 | — | 31 Dec 2025 | |
| David H. Deming |
3/4/5
|
Director |
0.31%
|
37,800
|
$38,556 | — | 05 Feb 2026 | |
| Curtis Lockshin |
3/4/5
|
Director |
0.29%
|
35,155
|
$35,858 | — | 05 Feb 2026 | |
| Jonathan E. Freeman |
3/4/5
|
Director |
0.27%
|
32,655
|
$33,308 | — | 05 Feb 2026 | |
| H. Paul Dorman |
3/4/5
|
Director |
—
class O/S missing
|
20,370
|
$30,759 | — | 15 Feb 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.2%
|
23,758
|
$24,946 | — | 31 Dec 2025 | |
| DRW Securities, LLC |
13F
|
Company |
0.19%
|
22,636
|
$23,767 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.17%
|
20,091
|
$21,096 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.12%
|
14,494
|
$15,219 | — | 31 Dec 2025 | |
| StoneX Group Inc. |
13F
|
Company |
0.1%
|
11,828
|
$12,419 | — | 31 Dec 2025 | |
| Robertson Stephens Wealth Management, LLC |
13F
|
Company |
0.09%
|
10,800
|
$11,340 | — | 31 Dec 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.08%
|
10,214
|
$11,000 | — | 31 Dec 2025 | |
| CAPTRUST FINANCIAL ADVISORS |
13F
|
Company |
0.08%
|
10,000
|
$10,500 | — | 31 Dec 2025 | |
| Caitlin Kontulis |
3/4/5
|
Secretary & VP Finance & Admin |
—
class O/S missing
|
10,643
|
$10,196 | — | 01 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
8,594
|
$9,024 | — | 31 Dec 2025 | |
| Robert M. Infarinato |
3/4/5
|
VP, CFO |
—
class O/S missing
|
11,000
|
$8,140 | — | 11 Sep 2024 | |
| Geert Cauwenbergh |
3/4/5
|
Director |
—
class O/S missing
|
4,235
|
$6,395 | — | 17 Feb 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.05%
|
6,000
|
$6,300 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
1,413
|
$1,483 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
1,135
|
$1,192 | — | 31 Dec 2025 | |
| ASSETMARK, INC |
13F
|
Company |
0%
|
110
|
$116 | — | 31 Dec 2025 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
9
|
$9 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Phio Pharmaceuticals Corp.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Curtis Lockshin | PHIO | Common Stock, $.0001 par value | Award | 89.5% | 16,600 | 35,155 | 05 Feb 2026 | Direct | ||
| Jonathan E. Freeman | PHIO | Common Stock, $.0001 par value | Award | 103.4% | 16,600 | 32,655 | 05 Feb 2026 | Direct | ||
| David H. Deming | PHIO | Common Stock, $.0001 par value | Award | 170% | 23,800 | 37,800 | 05 Feb 2026 | Direct | ||
| Lisa Cabott Carson | PHIO | Common Stock, $.0001 par value | Award | 100% | 47,000 | 94,000 | 05 Feb 2026 | Direct | ||
| Patricia A. Bradford | PHIO | Common Stock, $.0001 par value | Award | 68.1% | 18,500 | 45,651 | 05 Feb 2026 | Direct | ||
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Award | 41.2% | 120,000 | 411,421 | 05 Feb 2026 | Direct | ||
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Purchase | 1.75% | $5,150 | $1.03 | 5,000 | 291,421 | 31 Dec 2025 | Direct |
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Purchase | 1.78% | $5,100 | $1.02 | 5,000 | 286,421 | 23 Dec 2025 | Direct |
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Purchase | 1.81% | $5,700 | $1.14 | 5,000 | 281,421 | 21 Nov 2025 | Direct |
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Purchase | 1.84% | $6,350 | $1.27 | 5,000 | 276,421 | 18 Nov 2025 | Direct |
| Robert L. Ferrara | PHIO | Common Stock, $.0001 par value | Award | 147.4% | 23,100 | 38,766 | 11 Sep 2025 | Direct | ||
| David H. Deming | PHIO | Common Stock, $.0001 par value | Award | 14,000 | 14,000 | 11 Sep 2025 | Direct | |||
| Curtis Lockshin | PHIO | Common Stock, $.0001 par value | Award | 687.9% | 16,200 | 18,555 | 11 Sep 2025 | Direct | ||
| Jonathan E. Freeman | PHIO | Common Stock, $.0001 par value | Award | 1084.9% | 14,700 | 16,055 | 11 Sep 2025 | Direct | ||
| Lisa Cabott Carson | PHIO | Common Stock, $.0001 par value | Award | 47,000 | 47,000 | 11 Sep 2025 | Direct | |||
| Patricia A. Bradford | PHIO | Common Stock, $.0001 par value | Award | 225.1% | 18,800 | 27,151 | 11 Sep 2025 | Direct | ||
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Award | 1167.1% | 250,000 | 271,421 | 11 Sep 2025 | Direct | ||
| Robert J. Bitterman | PHIO | Common Stock, $.0001 par value | Tax liability | -16.1% | -4,111 | 21,421 | 11 Sep 2025 | Direct | ||
| Robert J. Bitterman | PHIO | Common Stock, $0.0001 par value | Purchase | 7.95% | $4,840 | $2.42 | 2,000 | 27,149 | 10 Jun 2025 | Direct |
| Robert L. Ferrara | PHIO | Common stock, $0.0001 par value | Purchase | 19% | $6,050 | $2.42 | 2,500 | 15,666 | 10 Jun 2025 | Direct |
| Robert J. Bitterman | PHIO | Common Stock, $0.0001 par value | Purchase | 6.34% | $4,125 | $2.75 | 1,500 | 25,149 | 09 Jun 2025 | Direct |
| Robert J. Bitterman | PHIO | Common Stock, $0.0001 par value | Purchase | 5.35% | $2,136 | $1.78 | 1,200 | 23,649 | 22 May 2025 | Direct |
| Robert J. Bitterman | PHIO | Common Stock, $0.0001 par value | Purchase | 15.4% | $5,310 | $1.77 | 3,000 | 22,449 | 21 May 2025 | Direct |
| Robert L. Ferrara | PHIO | Common stock, $0.0001 par value | Purchase | 23.4% | $4,550 | $1.82 | 2,500 | 13,166 | 20 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.